Related Experiment Videos
Biochemistry of azacitidine: a review
1Investigational Drug Branch, National Cancer Institute, Bethesda, MD 20892.
Cancer Treatment Reports
|October 1, 1987
Summary
Azacitidine disrupts RNA and DNA synthesis, inhibiting protein production and DNA methylation. This hypomethylation may drive its anti-leukemic effects but also poses carcinogenic risks.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Azacitidine is a cytidine analog impacting nucleic acid synthesis and function.
- It interferes with RNA processing and protein synthesis.
- As a deoxynucleotide, it inhibits DNA synthesis and methylation.
Purpose of the Study:
- To elucidate the molecular mechanisms of azacitidine's action.
- To understand its effects on DNA methylation and gene expression.
- To explore its dual role in antileukemic activity and potential carcinogenicity.
Main Methods:
- Investigated azacitidine incorporation into RNA and DNA.
- Assessed inhibition of DNA methyltransferase.
- Examined DNA hypomethylation and subsequent gene expression changes.
- Evaluated antileukemic, carcinogenic, and tumor-promoting properties in experimental models.
Main Results:
- Azacitidine incorporation into RNA alters synthesis and processing, inhibiting protein synthesis.
- Incorporation into DNA inhibits synthesis and blocks cytosine methylation via DNA methyltransferase inhibition.
- Resulting DNA hypomethylation is linked to gene activation, expression, and cell differentiation.
- Demonstrated potential antileukemic activity alongside carcinogenic and tumor-promoting effects in models.
Conclusions:
- Azacitidine exerts its effects through multiple molecular pathways involving RNA and DNA.
- DNA hypomethylation induced by azacitidine is a key mechanism for its antileukemic potential.
- The drug's activity is complex, with implications for both cancer treatment and potential adverse effects.